Chapters (90)
- Title Page
- Copyright Notice
- Contents
- Maps
- Chapter 1
- Chapter 2
- Chapter 3
- Chapter 4
- Chapter 5
- Chapter 6
- Chapter 7
- Chapter 8
- Chapter 9
- Chapter 10
- Chapter 11
- Chapter 12
- Chapter 13
- Chapter 14
- Chapter 15
- Chapter 16
- Chapter 17
- Chapter 18
- Chapter 19
- Chapter 20
- Chapter 21
- Chapter 22
- Chapter 23
- Chapter 24
- Chapter 25
- Chapter 26
- Chapter 27
- Chapter 28
- Chapter 29
- Chapter 30
- Chapter 31
- Chapter 32
- Chapter 33
- Chapter 34
- Chapter 35
- Chapter 36
- Chapter 37
- Chapter 38
- Chapter 39
- Chapter 40
- Chapter 41
- Chapter 42
- Chapter 43
- Chapter 44
- Chapter 45
- Chapter 46
- Chapter 47
- Chapter 48
- Chapter 49
- Chapter 50
- Chapter 51
- Chapter 52
- Chapter 53
- Chapter 54
- Chapter 55
- Chapter 56
- Chapter 57
- Chapter 58
- Chapter 59
- Chapter 60
- Chapter 61
- Chapter 62
- Chapter 63
- Chapter 64
- Chapter 65
- Chapter 66
- Chapter 67
- Chapter 68
- Chapter 69
- Chapter 70
- Chapter 71
- Chapter 72
- Chapter 73
- Chapter 74
- Chapter 75
- Chapter 76
- Chapter 77
- Chapter 78
- Chapter 79
- Chapter 80
- Chapter 81
- Chapter 82
- Chapter 83
- Acknowledgments
- By Kim Stanley Robinson from Tom Doherty Associates
- Copyright
Sandy begins his day on time. And while he’s only depending on himself, he stays on schedule. He tracks to a rundown area of the underlevel of Santa Ana, a mile or so north of South Coast Plaza, and unlocks the door to the warehouse he rents, after turning off all the alarms. Inside is his laboratory.
Today he starts with cytotoxicity assays, one of the most crucial parts of his work. Anyone can make drugs, after all; the trick is finding out if they’ll kill you or not without testing them personally. Or giving them to rats. Sandy doesn’t like killing rats. So he likes these assays.
Since the cornea’s epithelium will be the first place the drugs hit, epithelial cells get the first tests. A couple of days ago Sandy joined the crowd of biochem techs at the slaughterhouse and bought a package of cow eyeballs; now he takes them from the fridge and uses a device called a rubber policeman to scrape the epithelial cells off the basement membrane. Tapped into a petri dish with some growth medium, and a carefully measured dose of the drug in question—a new one, a variant of 3,4,5 trimethoxyamphetamine that he’s calling the Visionary—these cells will either proliferate or die or struggle somewhere in between, and staining them at the end of a week will tell the tale.
That assay set up, Sandy moves on to trickier stuff. The new drug’s effect on lymphocytes has to be checked as well, because blood will be carrying it a lot of the time. So Sandy begins a chromium release assay, injecting chromium 51 into lymphocytes, then centrifuging them so only the cells remain. At that point all the chromium in the mix is within the cells. Then the Visionary is added—in doses ranging from femptomolars up through picomolars, nanomolars, micromolars—and it all goes into a growth medium that should keep lymphocytes happy. But with the drug in there who knows. In any case dying or dead cells will release the chromium, and after another centrifuging, the free chromium found will be a good measure of the drug’s toxicity.
Later more tests of stationary cells and organ cells, particularly bone marrow cells, will be necessary. And eventually, after a lot of hours in the lab, Sandy will have a good idea of the Visionary’s toxicity. Neat. As for long-term negative effects of the new drug, well, that’s not so clear. That’s not in the guarantee. That’s not something he likes to think about, and neither does anybody else. None of these new drugs are well understood on the long-term level. But if there are problems down the road, they will no doubt come up with something, like they did for the various viral killers. Make the body into a micro-battlefield and win it all: the brain can finally prove it is smarter than viruses. Who knows what demon will fall next?